Recent ARCT News
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 • Business Wire • 04/25/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:05:52 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress • Business Wire • 03/07/2024 09:01:00 PM
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 02/26/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:35 PM
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 02/22/2024 01:30:00 PM
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 • Business Wire • 02/20/2024 02:00:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • Business Wire • 02/05/2024 01:30:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • PR Newswire (US) • 02/05/2024 01:30:00 PM
- CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster • Business Wire • 12/21/2023 01:00:00 PM
- CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster • PR Newswire (US) • 12/21/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 01:01:03 AM
- Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/04/2023 01:30:00 PM
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults • PR Newswire (US) • 11/28/2023 01:05:00 PM
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults • Business Wire • 11/28/2023 01:00:00 PM
- Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis • Dow Jones News • 11/27/2023 02:13:00 PM
- Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 11/27/2023 01:30:00 PM
- Keep An Eye Out: Pre-Market Movers And Analyst Recommendations • IH Market News • 11/15/2023 01:51:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:10:46 PM
- Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress • Business Wire • 11/14/2023 09:01:00 PM
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 • Business Wire • 10/25/2023 08:01:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 10/23/2023 08:01:00 PM
- Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government • Business Wire • 10/04/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:06:46 PM
- Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis • Business Wire • 09/26/2023 12:30:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM